nejm semaglutide ckd 🚨New Trial Results🚨 improves chronic kidney disease outcomes by 24% in pts with type 2 diabetes and CKD, in @NEJM today. ⬇️29% cardiovascular death ⬇️18% cardiovascular events ⬇️20% all-cause mortality Slower Semaglutides Are Poised to Remake

In addition to Xultophy and Soliqua, there is a new fixed-ratio combination drug on the horizon

Physical activity has been studied in relation to GLP-1 levels, with mixed findings

Tesamorelin is highly effective at reducing visceral (belly) fat, while Ipamorelin is a versatile peptide used for muscle recovery, better sleep, and anti-aging benefits

Studies have demonstrated that Hinge binds to HGF with high affinity blocking its dimerization and acting as a potent inhibitor of HGF-dependent cellular activities including MDCK D-Nle-X-Ile-NH-(CH 2 )s CONH 2 analogs modify HGF/Met mediated cell scattering in MDCK cells HGF/Met signaling is the hallmark effect of HGF/Met signaling

The risk is managed by close glucose monitoring and clinician-guided insulin changes